Adding docetaxel or abiraterone to ADT improves metastatic prostate cancer survival, with patient and cost factors the most important considerations when choosing between them, say guidelines.
Medscape Medical News
Original Article: ASCO Issues New Metastatic Prostate Cancer Treatment Guide